CXCR2 and hepatocellular carcinoma: AZD5069, a CXCR2 inhibitor that is used to reduce absolute neutrophil recruitment in bronchiectasis patients [174], is also under a phase I/II study in combination with durvalumab in patients with advanced hepatocellular carcinoma (HCC) [190].